Schrödinger

#4495

Rank

$1.75B

Marketcap

United States

Country

Leadership team

Dr. Ramy Farid Ph.D. (CEO, Pres & Director)

Dr. Richard A. Friesner Ph.D. (Co-Founder, Scientific Advisory Chairman and Director)

Mr. Kenneth Patrick Lorton (Exec. VP & CTO)

Products/ Services

Biotechnology, Enterprise Software, Pharmaceutical, Software

Number of Employees

500 - 1000

Headquarters

New York, New York, United States

Established

1990

Company Registration

SEC CIK number: 0001490978

Revenue

100M - 500M

Traded as

SDGR

Social Media

URL

https://www.schrodinger.com

Overview

Location

Recognition and Award

References

Summary

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

History

Schrödinger was founded in 1990 by Nobel Laureate Dr. Richard F. Schrodinger and a group of five eminent scientists to bring fundamental scientific breakthroughs in physics, chemistry, and materials science to industry. Through its industry-leading suite of software applications and services, Schrödinger helps researchers predict how drugs, materials, and molecules will behave, enabling more informed decision-making.

Mission

To improve human health and quality of life through development, distribution, and application of advanced computational methods that transform the way scientists design therapeutics and materials.

Vision

To be the global leader in the provision of quantum chemical programs, which will drive cutting-edge research and innovation.

Key Team

Dr. Robert Lorne Abel Ph.D. (Exec. VP, Chief Computational Scientist and Head of Modeling R&D)

Dr. Karen Akinsanya Ph.D. (Pres of R&D Therapeutics)

Mr. Shane Brauner (Exec. VP & Chief Information Officer)

Prof. William Goddard III (Co-Founder & Scientific Advisor)

Ms. Jaren Irene Madden (Sr. VP of Investor Relations & Corp. Communications)

Dr. Geoffrey Craig Porges MBBS (Exec. VP & CFO)

Ms. Yvonne Tran Esq. (Exec. VP, Chief Legal Officer & Sec.)

Recognition and Awards

Schrödinger has been recognized with numerous awards including the IBM International Prize in 2000 and the In-House One award for best software product in 2000. Schrödinger has also been presented with Innovation Awards from the National Science Foundation, the Department of Energy’s Office of Science and Advanced Technology Program, and the U.S. Navy.